Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t

Harrow Relaunches TRIESENCE®

07:00am, Thursday, 03'rd Oct 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable s

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

12:10pm, Wednesday, 02'nd Oct 2024
Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45.

Harrow Announces Nashville Expansion

12:02pm, Wednesday, 25'th Sep 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer o
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three inv
One can find stocks with superior estimated total returns by comparing their return drivers – earnings growth, dividend yield and valuation - to historic trends. This article compares investing in t

Harrow: Bulls On Parade

03:42pm, Friday, 16'th Aug 2024
Harrow stock is reaching new highs with significant short interest, but operational strength is driving a covering rally. Harrow is an eye care pharmaceutical company targeting the North American mark
Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago.
I have a diversified portfolio of stocks, funds, and bonds. My stocks are primarily dividend paying value stocks. One can find dividend stocks with superior estimated total returns by comparing their
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Harrow announced the successful production of the notoriously hard to manufacture drug, Triesence. There were many doubters, but management has been proven right in its confidence. This will result in
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Harrow Provides TRIESENCE® Relaunch Update

07:00am, Thursday, 20'th Jun 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three com
If you're looking for the best growth stocks to buy and hold through 2030, you should look into the many solid businesses other than the top tech mega-caps. I believe expanding your core growth holdin
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE